カテゴリ： 世界, 医療/バイオ, Market Monitor Global

喘息＆COPD治療薬のグローバル市場展望 2023年-2029年：ジェネリック治療薬、特許治療薬

■ 英語タイトル：Drugs for Asthma and COPD Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8487）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8487
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：114
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[喘息＆COPD治療薬のグローバル市場展望 2023年-2029年：ジェネリック治療薬、特許治療薬]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の喘息＆COPD治療薬市場規模と予測を収録しています。・世界の喘息＆COPD治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の喘息＆COPD治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の喘息＆COPD治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ジェネリック治療薬」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

喘息＆COPD治療薬のグローバル主要企業は、GSK、 Novartis、 Merck、 Abbott、 Boehringer Ingelheim、 AstraZeneca、 Roche、 Teva、 Vectura、 Pfizer、 Mylan、 Allergan、 Cipla、 Akorn、 Apotexなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、喘息＆COPD治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の喘息＆COPD治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の喘息＆COPD治療薬市場：タイプ別市場シェア、2022年
・ジェネリック治療薬、特許治療薬

世界の喘息＆COPD治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の喘息＆COPD治療薬市場：用途別市場シェア、2022年
・喘息、COPD

世界の喘息＆COPD治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の喘息＆COPD治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における喘息＆COPD治療薬のグローバル売上、2018年-2023年
・主要企業における喘息＆COPD治療薬のグローバル売上シェア、2022年
・主要企業における喘息＆COPD治療薬のグローバル販売量、2018年-2023年
・主要企業における喘息＆COPD治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
GSK、 Novartis、 Merck、 Abbott、 Boehringer Ingelheim、 AstraZeneca、 Roche、 Teva、 Vectura、 Pfizer、 Mylan、 Allergan、 Cipla、 Akorn、 Apotex

*************************************************************

・調査・分析レポートの概要
喘息＆COPD治療薬市場の定義
市場セグメント
世界の喘息＆COPD治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の喘息＆COPD治療薬市場規模
世界の喘息＆COPD治療薬市場規模：2022年 VS 2029年
世界の喘息＆COPD治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの喘息＆COPD治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の喘息＆COPD治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：ジェネリック治療薬、特許治療薬
喘息＆COPD治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：喘息、COPD
喘息＆COPD治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別喘息＆COPD治療薬市場規模 2022年と2029年
地域別喘息＆COPD治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
GSK、 Novartis、 Merck、 Abbott、 Boehringer Ingelheim、 AstraZeneca、 Roche、 Teva、 Vectura、 Pfizer、 Mylan、 Allergan、 Cipla、 Akorn、 Apotex
...

Drugs used as treatments for asthma and COPD
This report aims to provide a comprehensive presentation of the global market for Drugs for Asthma and COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Asthma and COPD. This report contains market size and forecasts of Drugs for Asthma and COPD in global, including the following market information:
Global Drugs for Asthma and COPD Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Drugs for Asthma and COPD Market Sales, 2018-2023, 2024-2029, (MT)
Global top five Drugs for Asthma and COPD companies in 2022 (%)
The global Drugs for Asthma and COPD market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Generic Drugs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Drugs for Asthma and COPD include GSK, Novartis, Merck, Abbott, Boehringer Ingelheim, AstraZeneca, Roche, Teva and Vectura, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drugs for Asthma and COPD manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Asthma and COPD Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (MT)
Global Drugs for Asthma and COPD Market Segment Percentages, by Type, 2022 (%)
Generic Drugs
Patented Drugs
Global Drugs for Asthma and COPD Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (MT)
Global Drugs for Asthma and COPD Market Segment Percentages, by Application, 2022 (%)
Asthma
COPD
Global Drugs for Asthma and COPD Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (MT)
Global Drugs for Asthma and COPD Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Asthma and COPD revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Drugs for Asthma and COPD revenues share in global market, 2022 (%)
Key companies Drugs for Asthma and COPD sales in global market, 2018-2023 (Estimated), (MT)
Key companies Drugs for Asthma and COPD sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Novartis
Merck
Abbott
Boehringer Ingelheim
AstraZeneca
Roche
Teva
Vectura
Pfizer
Mylan
Allergan
Cipla
Akorn
Apotex
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Asthma and COPD, market overview.
Chapter 2: Global Drugs for Asthma and COPD market size in revenue and volume.
Chapter 3: Detailed analysis of Drugs for Asthma and COPD manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Asthma and COPD in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Drugs for Asthma and COPD capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Drugs for Asthma and COPD Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Asthma and COPD Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Asthma and COPD Overall Market Size
2.1 Global Drugs for Asthma and COPD Market Size: 2022 VS 2029
2.2 Global Drugs for Asthma and COPD Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Drugs for Asthma and COPD Sales: 2018-2029
3 Company Landscape
3.1 Top Drugs for Asthma and COPD Players in Global Market
3.2 Top Global Drugs for Asthma and COPD Companies Ranked by Revenue
3.3 Global Drugs for Asthma and COPD Revenue by Companies
3.4 Global Drugs for Asthma and COPD Sales by Companies
3.5 Global Drugs for Asthma and COPD Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Drugs for Asthma and COPD Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Drugs for Asthma and COPD Product Type
3.8 Tier 1, Tier 2 and Tier 3 Drugs for Asthma and COPD Players in Global Market
3.8.1 List of Global Tier 1 Drugs for Asthma and COPD Companies
3.8.2 List of Global Tier 2 and Tier 3 Drugs for Asthma and COPD Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Drugs for Asthma and COPD Market Size Markets, 2022 & 2029
4.1.2 Generic Drugs
4.1.3 Patented Drugs
4.2 By Type – Global Drugs for Asthma and COPD Revenue & Forecasts
4.2.1 By Type – Global Drugs for Asthma and COPD Revenue, 2018-2023
4.2.2 By Type – Global Drugs for Asthma and COPD Revenue, 2024-2029
4.2.3 By Type – Global Drugs for Asthma and COPD Revenue Market Share, 2018-2029
4.3 By Type – Global Drugs for Asthma and COPD Sales & Forecasts
4.3.1 By Type – Global Drugs for Asthma and COPD Sales, 2018-2023
4.3.2 By Type – Global Drugs for Asthma and COPD Sales, 2024-2029
4.3.3 By Type – Global Drugs for Asthma and COPD Sales Market Share, 2018-2029
4.4 By Type – Global Drugs for Asthma and COPD Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Drugs for Asthma and COPD Market Size, 2022 & 2029
5.1.2 Asthma
5.1.3 COPD
5.2 By Application – Global Drugs for Asthma and COPD Revenue & Forecasts
5.2.1 By Application – Global Drugs for Asthma and COPD Revenue, 2018-2023
5.2.2 By Application – Global Drugs for Asthma and COPD Revenue, 2024-2029
5.2.3 By Application – Global Drugs for Asthma and COPD Revenue Market Share, 2018-2029
5.3 By Application – Global Drugs for Asthma and COPD Sales & Forecasts
5.3.1 By Application – Global Drugs for Asthma and COPD Sales, 2018-2023
5.3.2 By Application – Global Drugs for Asthma and COPD Sales, 2024-2029
5.3.3 By Application – Global Drugs for Asthma and COPD Sales Market Share, 2018-2029
5.4 By Application – Global Drugs for Asthma and COPD Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Drugs for Asthma and COPD Market Size, 2022 & 2029
6.2 By Region – Global Drugs for Asthma and COPD Revenue & Forecasts
6.2.1 By Region – Global Drugs for Asthma and COPD Revenue, 2018-2023
6.2.2 By Region – Global Drugs for Asthma and COPD Revenue, 2024-2029
6.2.3 By Region – Global Drugs for Asthma and COPD Revenue Market Share, 2018-2029
6.3 By Region – Global Drugs for Asthma and COPD Sales & Forecasts
6.3.1 By Region – Global Drugs for Asthma and COPD Sales, 2018-2023
6.3.2 By Region – Global Drugs for Asthma and COPD Sales, 2024-2029
6.3.3 By Region – Global Drugs for Asthma and COPD Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Drugs for Asthma and COPD Revenue, 2018-2029
6.4.2 By Country – North America Drugs for Asthma and COPD Sales, 2018-2029
6.4.3 US Drugs for Asthma and COPD Market Size, 2018-2029
6.4.4 Canada Drugs for Asthma and COPD Market Size, 2018-2029
6.4.5 Mexico Drugs for Asthma and COPD Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Drugs for Asthma and COPD Revenue, 2018-2029
6.5.2 By Country – Europe Drugs for Asthma and COPD Sales, 2018-2029
6.5.3 Germany Drugs for Asthma and COPD Market Size, 2018-2029
6.5.4 France Drugs for Asthma and COPD Market Size, 2018-2029
6.5.5 U.K. Drugs for Asthma and COPD Market Size, 2018-2029
6.5.6 Italy Drugs for Asthma and COPD Market Size, 2018-2029
6.5.7 Russia Drugs for Asthma and COPD Market Size, 2018-2029
6.5.8 Nordic Countries Drugs for Asthma and COPD Market Size, 2018-2029
6.5.9 Benelux Drugs for Asthma and COPD Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Drugs for Asthma and COPD Revenue, 2018-2029
6.6.2 By Region – Asia Drugs for Asthma and COPD Sales, 2018-2029
6.6.3 China Drugs for Asthma and COPD Market Size, 2018-2029
6.6.4 Japan Drugs for Asthma and COPD Market Size, 2018-2029
6.6.5 South Korea Drugs for Asthma and COPD Market Size, 2018-2029
6.6.6 Southeast Asia Drugs for Asthma and COPD Market Size, 2018-2029
6.6.7 India Drugs for Asthma and COPD Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Drugs for Asthma and COPD Revenue, 2018-2029
6.7.2 By Country – South America Drugs for Asthma and COPD Sales, 2018-2029
6.7.3 Brazil Drugs for Asthma and COPD Market Size, 2018-2029
6.7.4 Argentina Drugs for Asthma and COPD Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Drugs for Asthma and COPD Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Drugs for Asthma and COPD Sales, 2018-2029
6.8.3 Turkey Drugs for Asthma and COPD Market Size, 2018-2029
6.8.4 Israel Drugs for Asthma and COPD Market Size, 2018-2029
6.8.5 Saudi Arabia Drugs for Asthma and COPD Market Size, 2018-2029
6.8.6 UAE Drugs for Asthma and COPD Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 GSK
7.1.1 GSK Company Summary
7.1.2 GSK Business Overview
7.1.3 GSK Drugs for Asthma and COPD Major Product Offerings
7.1.4 GSK Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.1.5 GSK Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Drugs for Asthma and COPD Major Product Offerings
7.2.4 Novartis Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Merck
7.3.1 Merck Company Summary
7.3.2 Merck Business Overview
7.3.3 Merck Drugs for Asthma and COPD Major Product Offerings
7.3.4 Merck Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.3.5 Merck Key News & Latest Developments
7.4 Abbott
7.4.1 Abbott Company Summary
7.4.2 Abbott Business Overview
7.4.3 Abbott Drugs for Asthma and COPD Major Product Offerings
7.4.4 Abbott Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.4.5 Abbott Key News & Latest Developments
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Company Summary
7.5.2 Boehringer Ingelheim Business Overview
7.5.3 Boehringer Ingelheim Drugs for Asthma and COPD Major Product Offerings
7.5.4 Boehringer Ingelheim Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.5.5 Boehringer Ingelheim Key News & Latest Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Company Summary
7.6.2 AstraZeneca Business Overview
7.6.3 AstraZeneca Drugs for Asthma and COPD Major Product Offerings
7.6.4 AstraZeneca Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.6.5 AstraZeneca Key News & Latest Developments
7.7 Roche
7.7.1 Roche Company Summary
7.7.2 Roche Business Overview
7.7.3 Roche Drugs for Asthma and COPD Major Product Offerings
7.7.4 Roche Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.7.5 Roche Key News & Latest Developments
7.8 Teva
7.8.1 Teva Company Summary
7.8.2 Teva Business Overview
7.8.3 Teva Drugs for Asthma and COPD Major Product Offerings
7.8.4 Teva Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.8.5 Teva Key News & Latest Developments
7.9 Vectura
7.9.1 Vectura Company Summary
7.9.2 Vectura Business Overview
7.9.3 Vectura Drugs for Asthma and COPD Major Product Offerings
7.9.4 Vectura Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.9.5 Vectura Key News & Latest Developments
7.10 Pfizer
7.10.1 Pfizer Company Summary
7.10.2 Pfizer Business Overview
7.10.3 Pfizer Drugs for Asthma and COPD Major Product Offerings
7.10.4 Pfizer Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.10.5 Pfizer Key News & Latest Developments
7.11 Mylan
7.11.1 Mylan Company Summary
7.11.2 Mylan Drugs for Asthma and COPD Business Overview
7.11.3 Mylan Drugs for Asthma and COPD Major Product Offerings
7.11.4 Mylan Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.11.5 Mylan Key News & Latest Developments
7.12 Allergan
7.12.1 Allergan Company Summary
7.12.2 Allergan Drugs for Asthma and COPD Business Overview
7.12.3 Allergan Drugs for Asthma and COPD Major Product Offerings
7.12.4 Allergan Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.12.5 Allergan Key News & Latest Developments
7.13 Cipla
7.13.1 Cipla Company Summary
7.13.2 Cipla Drugs for Asthma and COPD Business Overview
7.13.3 Cipla Drugs for Asthma and COPD Major Product Offerings
7.13.4 Cipla Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.13.5 Cipla Key News & Latest Developments
7.14 Akorn
7.14.1 Akorn Company Summary
7.14.2 Akorn Business Overview
7.14.3 Akorn Drugs for Asthma and COPD Major Product Offerings
7.14.4 Akorn Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.14.5 Akorn Key News & Latest Developments
7.15 Apotex
7.15.1 Apotex Company Summary
7.15.2 Apotex Business Overview
7.15.3 Apotex Drugs for Asthma and COPD Major Product Offerings
7.15.4 Apotex Drugs for Asthma and COPD Sales and Revenue in Global (2018-2023)
7.15.5 Apotex Key News & Latest Developments
8 Global Drugs for Asthma and COPD Production Capacity, Analysis
8.1 Global Drugs for Asthma and COPD Production Capacity, 2018-2029
8.2 Drugs for Asthma and COPD Production Capacity of Key Manufacturers in Global Market
8.3 Global Drugs for Asthma and COPD Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Drugs for Asthma and COPD Supply Chain Analysis
10.1 Drugs for Asthma and COPD Industry Value Chain
10.2 Drugs for Asthma and COPD Upstream Market
10.3 Drugs for Asthma and COPD Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Drugs for Asthma and COPD Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 好酸球性喘息治療薬のグローバル市場展望 2023年-2029年：点滴静注型、皮下注射型
  • 咳喘息（CVA）治療薬のグローバル市場展望 2023年-2029年：気管支拡張剤、ロイコトリエン拮抗剤、肥満細胞安定剤、コルチコステロイド、モノクローナル抗体
  • 世界の喘息治療薬市場2022年：市場規模予測（～2028年）
  • イロプロスト薬のグローバル市場展望 2023年-2029年：吸入型、静脈内型
  • うつ病治療薬のグローバル市場展望 2023年-2029年：SSRI、SNRI、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8487 )"喘息＆COPD治療薬のグローバル市場展望 2023年-2029年：ジェネリック治療薬、特許治療薬" (英文：Drugs for Asthma and COPD Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。